A SINGLE CENTER, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, TWO-PERIOD CROSSOVER STUDY TO ASSESS THE BIOEQUIVALENCE OF AN ORAL MERCAPTOPURINE SUSPENSION 100 mg / 5 mL VERSUS AN ORAL MERCAPTOPURINE TABLET 50 mg (PURINETHOL®) IN AT LEAST 62 HEALTHY MALE SUBJECTS UNDER FASTING CONDITIONS
- Healthy male subjects, 18 years to 50 years inclusive at time of last administration
of the IMP.
- Body Mass Index (BMI) between 18.5 and 30 kg/m2.
- Body mass not less than 50 kg.
- Medical history, physical examination, standard 12-lead electrocardiogram (ECG) and
laboratory investigations: Findings clinically acceptable or within laboratory
reference ranges for the relevant laboratory tests, unless the investigator considers
the deviation to be irrelevant for the purpose of the study.
- Current alcohol use > 21 units of alcohol per week for males.
- Regular exposure to substances of abuse (other than alcohol) within the past year.
- Use of any medication, prescribed or over-the-counter or herbal remedies, within 2
weeks prior to the first administration of IMP except if this will not affect the
outcome of the study in the opinion of the investigator.
- Participation in another study with an experimental drug, where the last
administration of the previous IMP was within 8 weeks before the first administration
of IMP in this study.
- Treatment within the previous 3 months before the first administration of IMP with
any drug with a well-defined potential for adversely affecting a major organ or
- A major illness during the 3 months before commencement of the screening period.
- Subjects with a deficient, low or intermediate TPMT enzyme activity by means of
- Subjects who participated in previous azathioprine/mercaptopurine studies within six
months will be excluded.
- Relevant history or laboratory or clinical findings indicative of acute or chronic
disease, likely to influence study outcome.
- Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the
first administration of IMP.
- Diagnosis of hypotension or hypertension made during the screening period or current
diagnosis of hypertension.
- Resting pulse of > 100 beats per minute or < 45 beats per minute during the screening
period, either supine or standing.
- Positive testing for HIV and/or Hepatitis B and/or Hepatitis C.
- Positive urine screen for drugs of abuse.
- Positive urine screen for tobacco use.
- Subjects who plan to procreate within 12 weeks after IMP administration, or not
willing to practice reliable forms of contraception during the study and for at least
12 weeks after the last dose of IMP.
- Immunization using a live organism vaccine within 4 weeks prior to the first dosing
- Any specific IMP safety concern.